Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 9Carcinoma, Transitional Cell 4Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Ureteral Neoplasms 2Urothelial Cancer 1Urologic Neoplasms 1Urogenital Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Kidney Neoplasms 1

Interventions

pembrolizumab 14Nivolumab 13Sunitinib 12Axitinib 9cabozantinib 8belzutifan 8Ipilimumab 7Everolimus 5atezolizumab 4Sorafenib 4temsirolimus 3perifosine 3motexafin gadolinium 3Drug Therapy 3spartalizumab 2palbociclib 2liposomal doxorubicin 2lenvatinib 2entinostat 2ciforadenant 2belinostat 2avelumab 2Paclitaxel 2Immunotherapy 2G250 monoclonal antibody 2Fluorouracil 2Docetaxel 2Dexamethasone 2Cetuximab 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Kidney Neoplasms × vinflunine × Clear all
NCT00101608 2010-03-02

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Bristol-Myers Squibb

Phase 2 Completed
150 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡